Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 9/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18500474 | 0.85 | BRD4 (0.39) | BRD4GRM4CYP1A2CHRNB2CHRNA4 | |
| SCHEMBL12974388 | 0.83 | TRPA1 (0.41) | ALDH1A1GAAALOX15HSD17B10BRD4 | |
| SCHEMBL24758379 | 0.80 | GRM4 (0.36) | BRD4GRM4CYP1A2CHRNB2CHRNA4 | |
| SCHEMBL24758377 | 0.80 | GRM4 (0.36) | BRD4GRM4CYP1A2CHRNB2CHRNA4 | |
| SCHEMBL23030530 | 0.73 | USP2 (0.45) | ALDH1A1GAAUSP2PKMHPGD | |
| SCHEMBL16806144 | 0.73 | ALDH1A1 (0.43) | ALDH1A1GAAUSP2PKMHPGD | |
| SCHEMBL8170902 | 0.73 | NPC1 (0.42) | ALDH1A1HPGDBRD4GRM4CYP1A2 | |
| SCHEMBL8203287 | 0.72 | GABRA1 (0.42) | BRD4GRM4CYP1A2 | |
| SCHEMBL12974404 | 0.72 | PTPN1 (0.37) | ALDH1A1GAAPKMALOX15HSD17B10 | |
| SCHEMBL8415607 | 0.72 | BRD4 (0.40) | BRD4CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10457667-B2 | Indolin-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | disclosed |
| EP-2565193-A1 | Compositions and methods for inhibition of the JAK pathway | Rigel Pharmaceuticals, Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| WO-2010085684-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10457667-B2 | Indolin-2-one derivatives | GRIN2B, GRIN2A, GRIN2D | ALDH1A1 1225/4885GAA 4293/4885USP2 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.